PFKFB2 and breast cancer: Additional study by Ruprecht et al. unveiled that phosphorylation of Ser466 of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 (PFKFB2) is inhibited following lapatinib treatment in lapatinib-sensitive BT-474 breast cancer cell line, however it recovers to its initial levels of phosphorylation in lapatinib-resistant BT-474 clone BT-474-J4 [42].